[ad_1]
Opportunities Featuring Proprietary Surface Coated Technologies
CARLSBAD, Calif., April 7, 2022 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, today announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company’s nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.
“We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects,” stated Carl St. BernardPresident and Chief Executive Officer of CeloNova. “This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies.”
“I fully support CeloNova’s new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F,” stated Professor Dr. Michael GrunzeFormer …
Full story available on Benzinga.com
[ad_2]
Source link
